ArticleDrug and alcohol dependence2020
Age disparities in six-month treatment retention for opioid use disorder.
Article in Drug and alcohol dependence, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- Patient Profiles of Buprenorphine Initiators in General Healthcare Settings: A Latent Class Approach.Journal of general internal medicine · 2026Article
- Characterization of patients declining to participate in opioid overdose prevention clinical research in an emergency department setting.Journal of substance use and addiction treatment · 2026Article
- Review
- Association Between Congenital Heart Disease Complexity, Mental Health Conditions and Opioid Use Disorder.JACC. Advances · 2025Article
- Assessing inequities in buprenorphine treatment across the care cascade.Drug and alcohol dependence · 2025Observational
- Exploring the Determinants of Treatment Completion Among Youth Who Received Medication-Assisted Treatment in the United States.Healthcare (Basel, Switzerland) · 2025Article
- Engagement, initiation, and retention in medication treatment for opioid use disorder among young adults: A narrative review of challenges and opportunities.Journal of substance use and addiction treatment · 2024Review
- An Assertive Community Intervention to Engage Youth with Opioid Use Disorder and Their Families.Child and adolescent psychiatric clinics of North America · 2024Review
- Opioid use disorder (OUD) and treatment for opioid problems among OUD symptom subtypes in individuals misusing opioids.Drug and alcohol dependence reports · 2024Article
- Article
- Retention in Telehealth Treatment for Opioid Use Disorder Among Rural Populations: A Retrospective Cohort Study.Telemedicine journal and e-health : the official journal of the American Telemedicine Association · 2023Article
- Article
- Initiation and Treatment Discontinuation of Medications for Opioid Use Disorder in Pregnant People Compared With Nonpregnant People.Obstetrics and gynecology · 2023Article
- Becoming our young people's case managers: caregivers' experiences, needs, and ideas for improving opioid use treatments for young people using opioids.Substance abuse treatment, prevention, and policy · 2022Article
- Analysis of Stimulant Prescriptions and Drug-Related Poisoning Risk Among Persons Receiving Buprenorphine Treatment for Opioid Use Disorder.JAMA network open · 2022Article
- "We need to build a better bridge": findings from a multi-site qualitative analysis of opportunities for improving opioid treatment services for youth.Harm reduction journal · 2022Article
- An examination between treatment type and treatment retention in persons with opioid and co-occurring alcohol use disorders.Drug and alcohol dependence · 2021Observational
- Association Between Benzodiazepine or Z-Drug Prescriptions and Drug-Related Poisonings Among Patients Receiving Buprenorphine Maintenance: A Case-Crossover Analysis.The American journal of psychiatry · 2021Article
- Association of Opioid Use Disorder Treatment With Alcohol-Related Acute Events.JAMA network open · 2021Article
- Characteristics of mHealth therapy app engagement by young adults with OUD.Journal of addictive diseasesObservational
Corrections and comments
- Erratum issued
Authors and funding
7 authors.
Funding
Abstract
BACKGROUND AND
aimsAdolescents with opioid use disorder (OUD) are an understudied and vulnerable population. We examined the association between age and six-month treatment retention, and whether any such association was moderated by medication treatment.
methodsIn this retrospective cohort study, we used an insurance database with OUD treatment claims from 2006-2016. We examined 261,356 OUD treatment episodes in three age groups: adolescents (ages 12-17), young adults (18-25) and older adults (26-64). We used logistic regression to estimate prevalence of six-month retention before and after stratification by treatment type (buprenorphine, naltrexone, or psychosocial only). Insurance differences (commercial vs Medicaid) in medication treatment prevalence were also assessed.
resultsAdolescents were less likely to be retained compared to adults (17.6 %; 95 % CI 16.5-18.7 % for adolescents; 25.1 %; 95 % CI 24.7-25.4 % for young adults; 33.3 %; 95 % CI 33.0-33.5 % for older adults). This disparity was reduced after adjusting for treatment type. For all ages, buprenorphine was more strongly associated with retention than naltrexone or psychosocial treatment. Adolescents who received buprenorphine were more than four times as likely to be retained in treatment (44.8 %; 95 % CI 40.6-49.0) compared to those who received psychosocial services (9.7 %; 95 % CI 8.8-10.8). Persons with commercial insurance were more likely to receive medication than those with Medicaid (73 % vs 36 %, (χ
conclusionsAge disparities in six-month treatment retention are strongly related to age disparities in medication treatment. Results point to need for improved implementation of medication treatment for persons with OUD, regardless of age or insurance status.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.